Business Description
EQRx Inc
NAICS : 541715
SIC : 2834
Description
EQRx Inc is a biotechnology company. the company has more than 10 programs in its pipeline, including clinical, preclinical and drug engineering targets for the treatment of oncology and immune-inflammatory conditions. The program includes Aumolertinib, Lerociclib, Sugemalimab, Nofazinlimab, and others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 588.5 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | 30.95 | |||||
| 12-1 Month Momentum % | -59.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 18.78 | |||||
| Quick Ratio | 18.78 | |||||
| Cash Ratio | 18.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 0.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -19.96 | |||||
| ROA % | -18.77 | |||||
| ROIC % | -1047.78 | |||||
| ROC (Joel Greenblatt) % | -5154.97 | |||||
| ROCE % | -23.14 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.97 | |||||
| Price-to-Tangible-Book | 0.97 | |||||
| EV-to-EBIT | 0.22 | |||||
| EV-to-Forward-EBIT | -1.52 | |||||
| EV-to-EBITDA | 0.23 | |||||
| EV-to-Forward-EBITDA | -1.52 | |||||
| EV-to-Forward-Revenue | 66.62 | |||||
| EV-to-FCF | 0.21 | |||||
| Price-to-Net-Current-Asset-Value | 0.98 | |||||
| Price-to-Net-Cash | 0.99 | |||||
| Earnings Yield (Greenblatt) % | 454.55 | |||||
| FCF Yield % | -29.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EQRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
EQRx Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.54 | ||
| Beta | 0 | ||
| Volatility % | 59.82 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0.122857 | ||
| 20-Day SMA ($) | 0 | ||
| 12-1 Month Momentum % | -59.63 | ||
| 52-Week Range ($) | 1.58 - 4.75 | ||
| Shares Outstanding (Mil) | 487.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
EQRx Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
EQRx Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
EQRx Inc Frequently Asked Questions
What is EQRx Inc(EQRX)'s stock price today?
The current price of EQRX is $2.34. The 52 week high of EQRX is $4.75 and 52 week low is $1.58.
When is next earnings date of EQRx Inc(EQRX)?
The next earnings date of EQRx Inc(EQRX) is 2025-02-23 Est..
Does EQRx Inc(EQRX) pay dividends? If so, how much?
EQRx Inc(EQRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers